It has been suggested that the interaction between PD-1 and PD-L2 could limit the development of a T-cell response and explain the failure of PD-1/PD-L1 immunotherapy trials in older non-glioma related trials (22). This evidence concerns the gene PDCD1LG2 and central nervous system cancer.